Reports On Company: Divi's Lab
| Divi’s Laboratories Ltd is strategically poised to capitalize on emerging opportunities. Buy for target price Rs 4041: SMIFS | |
| Company: | Divi's Lab |
| Brokerage: | SMIFS |
| Date of report: | August 14, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 8.3% |
| Summary: | Divi is strategically poised to capitalize on emerging opportunities presented by recently off-patent molecules. Company is seeing softening of RM and logistics costs which will improve the margins further. We forecast Revenue / EBITDA / PAT CAGR during FY23- 25E at 16.7%/31.5%/27.5%. We value the stock based on SOTP valuation strategy and arrive at a target price of INR 4,041. Accumulate |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |
| Divi’s Laboratories Research Report By ICICI-Direct | |
| Company: | Divi's Lab |
| Brokerage: | ICICI-Direct |
| Date of report: | December 30, 2020 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 17% |
| Summary: | Strong H1; more capex amid better visibility… |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |
| Divi’s Laboratories Research Report By ICICI Securities | |
| Company: | Divi's Lab |
| Brokerage: | ICICI Securities |
| Date of report: | December 9, 2020 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 7.5% |
| Summary: | Sustainable strong growth play |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |